Filing Flows

Filing Flows › 8-K events › Viridian Therapeutics

Viridian Therapeutics: regulation fd disclosure

Form 8-K filed Nov 9, 2026 · items 7.01, 8.01

FDA decisionsViridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

What the filing says

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy volunteers, with 74% redu

Read the filing on SEC EDGAR →

What usually followsAcross 44,918 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Viridian Therapeutics at a glance

Latest quarterQ3 2026
Revenue$25.8M
Revenue Y/Y-64%
Operating margin-401.8%
IndustryPharmaceutical Preparations

Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%. The chart follows the revenue to costs, profit and cash.

Viridian Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.